Alder BioPharmaceuticals (ALDR) PT Raised to $26.00

Alder BioPharmaceuticals (NASDAQ:ALDR) had its price target lifted by BMO Capital Markets to $26.00 in a report released on Tuesday, The Fly reports. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. ValuEngine upgraded Alder BioPharmaceuticals from a strong sell rating to a sell rating in a report on Saturday, September 30th. Mizuho reiterated a buy rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, November 8th. BidaskClub upgraded Alder BioPharmaceuticals from a strong sell rating to a sell rating in a report on Friday, December 29th. Cowen started coverage on Alder BioPharmaceuticals in a report on Tuesday, September 26th. They issued an outperform rating and a $20.00 target price for the company. Finally, Royal Bank of Canada started coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They issued an outperform rating and a $17.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $27.79.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded down $0.20 on Tuesday, hitting $17.35. The stock had a trading volume of 2,400,000 shares, compared to its average volume of 1,170,000. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $25.45. The company has a market capitalization of $1,170.00, a P/E ratio of -3.23 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the company earned ($0.70) EPS. sell-side analysts anticipate that Alder BioPharmaceuticals will post -5.14 EPS for the current fiscal year.

In related news, insider Mark James Litton sold 16,519 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.60% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in ALDR. AXA boosted its position in Alder BioPharmaceuticals by 199.9% in the third quarter. AXA now owns 992,083 shares of the biopharmaceutical company’s stock worth $12,153,000 after purchasing an additional 661,253 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Alder BioPharmaceuticals by 611.7% in the third quarter. Cubist Systematic Strategies LLC now owns 23,373 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 20,089 shares during the last quarter. Jane Street Group LLC purchased a new position in Alder BioPharmaceuticals in the third quarter worth $184,000. Cornerstone Capital Management Holdings LLC. boosted its position in Alder BioPharmaceuticals by 23.3% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 37,620 shares of the biopharmaceutical company’s stock worth $459,000 after purchasing an additional 7,100 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Alder BioPharmaceuticals in the third quarter worth $752,000. 96.80% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Alder BioPharmaceuticals (ALDR) PT Raised to $26.00” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/10/alder-biopharmaceuticals-aldr-pt-raised-to-26-00.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

The Fly

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit